Duligotuzumab

DB12142InvestigationalProtein Based Therapies

Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.

Mechanism: Pharmacologically active on Epidermal growth factor receptor and Receptor tyrosine-protein kinase erbB-3
Curator reviewed
Code names: MEHD7945A

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

420Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Duligotuzumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.